Emery Pharma, a leading pharmaceutical research organization based in the San Francisco Bay Area, and Abvaccc, a renowned biotechnology company headquartered in Rockville, Maryland, are pleased to announce a strategic collaboration to develop a super fast-acting intranasal naloxone. This innovative product aims to reverse opioid overdoses rapidly and effectively, addressing a critical public health need in combating the opioid crisis.

The collaboration leverages Emery Pharma’s expertise in pharmaceutical development and regulatory compliance with Abvacc’s established capabilities in developing pharmacokinetic models. Together, the two companies will focus on optimizing the formulation of intranasal naloxone, testing its pharmacokinetics in preclinical models, and advancing it into human clinical trials, with the ultimate goal of FDA approval and commercialization.

Dr. Ron Najafi, CEO of Emery Pharma, expressed his enthusiasm for the partnership:

"At Emery Pharma, we are deeply committed to addressing the opioid epidemic with innovative solutions. Our collaboration with Abvacc combines our strengths to develop a life-saving, super fast-acting intranasal naloxone. We are excited to work with Dr. Aman and the exceptional team at Abvacc to accelerate this critical project and bring hope to patients and families affected by opioid addiction."

Dr. Javad Aman, CEO of Abvacc, shared his perspective on the collaboration:

"This partnership with Emery Pharma represents an extraordinary opportunity to develop a product that could save countless lives. “Patients are waiting”, and we are working at the speed of light to make this vision a reality. Together, we are leveraging our expertise and shared passion to address one of the most urgent challenges in public health."

The partnership underscores both companies' commitment to leveraging innovation and collaboration to address the ongoing opioid crisis. Emery Pharma and Abvacc are aligned in their mission to deliver transformative solutions that save lives and improve global health.

About Emery Pharma

Emery Pharma is a pharmaceutical research and development organization based in Alameda, California, in the San Francisco Bay Area. Specializing in drug discovery, bioanalysis, and regulatory compliance, Emery Pharma works with pharmaceutical, biotech, and medical device companies to advance innovative products.

About Abvacc

Abvacc is a biotechnology company based in Rockville, Maryland, specializing in developing animal models for testing therapeutic efficacy and pharmacokinetics. Abvacc’s mission is to advance science and technology to address unmet medical needs and improve patient outcomes.